BioCardia (BCDA) Competitors $1.20 -0.34 (-22.15%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. LTRN, PEPG, NBRV, RNXT, ATHE, AADI, ANVS, GRCE, JSPR, and IPSCShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), Annovis Bio (ANVS), Grace Therapeutics (GRCE), Jasper Therapeutics (JSPR), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio Grace Therapeutics Jasper Therapeutics Century Therapeutics BioCardia (NASDAQ:BCDA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts prefer BCDA or LTRN? BioCardia presently has a consensus target price of $25.00, indicating a potential upside of 1,992.05%. Lantern Pharma has a consensus target price of $25.00, indicating a potential upside of 516.52%. Given BioCardia's stronger consensus rating and higher possible upside, research analysts clearly believe BioCardia is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BCDA or LTRN more profitable? Lantern Pharma's return on equity of -99.89% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -19,117.42% -246.92% Lantern Pharma N/A -99.89%-81.58% Do institutionals & insiders believe in BCDA or LTRN? 20.6% of BioCardia shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, BCDA or LTRN? BioCardia has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$60K115.52-$7.95M-$1.85-0.65Lantern PharmaN/AN/A-$20.78M-$1.78-2.28 Does the media prefer BCDA or LTRN? In the previous week, BioCardia had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 6 mentions for BioCardia and 5 mentions for Lantern Pharma. BioCardia's average media sentiment score of 0.64 beat Lantern Pharma's score of -0.46 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, BCDA or LTRN? BioCardia has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. SummaryBioCardia beats Lantern Pharma on 9 of the 14 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.82M$3.13B$5.75B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-0.6421.2176.6126.83Price / Sales115.52255.25452.6189.74Price / CashN/A45.4837.2260.63Price / Book6.649.6513.926.37Net Income-$7.95M-$53.02M$3.29B$271.28M7 Day Performance-47.36%0.49%0.26%1.87%1 Month Performance-36.44%4.93%4.92%7.43%1 Year Performance-61.20%11.01%85.89%30.62% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.2616 of 5 stars$1.20-22.1%$25.00+1,992.1%-45.0%$6.82M$60K-0.6440News CoverageGap DownHigh Trading VolumeLTRNLantern Pharma2.0575 of 5 stars$4.06-5.8%$25.00+515.8%+2.6%$46.54MN/A-2.2820PEPGPepGen2.6476 of 5 stars$1.49+6.4%$7.67+414.5%-79.5%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.2122 of 5 stars$1.14-8.1%$7.50+557.9%+20.8%$45.44M$40K-3.006News CoverageNegative NewsShort Interest ↑ATHEAlterity Therapeutics2.0023 of 5 stars$5.17+2.0%$12.00+132.1%+247.9%$44.96MN/A0.0010Gap DownHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+6.0%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.1749 of 5 stars$2.34+2.1%$17.33+641.4%-73.3%$44.62MN/A-1.153GRCEGrace Therapeutics2.8674 of 5 stars$3.24+1.3%$12.00+270.4%N/A$44.25MN/A-3.77N/ANews CoverageJSPRJasper Therapeutics3.105 of 5 stars$2.65-2.6%$28.75+984.9%-89.9%$44.21MN/A-0.4420Gap UpIPSCCentury Therapeutics1.845 of 5 stars$0.51+1.1%$3.75+634.9%-70.4%$43.60M$6.59M-1.76170 Related Companies and Tools Related Companies LTRN Alternatives PEPG Alternatives NBRV Alternatives RNXT Alternatives ATHE Alternatives AADI Alternatives ANVS Alternatives GRCE Alternatives JSPR Alternatives IPSC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCDA Stock Alerts